(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Nov. 20, 2026 (GLOBE NEWSWIRE) -- "HIV Clinical Trials - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering. The global HIV clinical trials market was valued at US$1.5 billion in 2025 and is projected to reach US$2.1 billion by 2032, expanding at a compound annual growth rate (CAGR) of 4.8%. Market growth is supported by sustained investment in HIV research, increased development of long-acting antiretroviral therapies, expanding vaccine pipelines, and the adoption of advanced technologies across clinical research.
Key HIV Clinical Trials Market Trends and Growth Drivers
Researchers are advancing long-acting antiretrovirals, functional cure strategies, preventive vaccines, combination therapies, and antibody-based treatments. Pharmaceutical and biopharmaceutical companies, governments, academic institutions, and nonprofit organizations are investing in treatment regimens designed to improve adherence, strengthen viral suppression, address drug resistance, and reduce adverse effects.
Injectable and implantable antiretroviral therapies are reshaping clinical development by offering alternatives to daily oral medication. Pre-exposure prophylaxis, broadly neutralizing antibodies, nanomedicine, and personalized treatment strategies are also gaining prominence as clinical programs pursue more durable and targeted approaches to HIV treatment and prevention.
Technology Innovation in HIV Clinical Research
Artificial intelligence, genomic sequencing, CRISPR-based gene editing, digital health platforms, and predictive analytics are transforming HIV clinical trial design and execution. Artificial intelligence supports patient recruitment, biomarker identification, protocol optimization, and predictive modeling. Gene-editing research is investigating long-term viral suppression and the potential elimination of persistent HIV reservoirs.
mRNA vaccine platforms have also created new opportunities for preventive HIV vaccine research. Meanwhile, decentralized and virtual clinical trial models-including telemedicine, remote monitoring, and digital patient engagement-are improving recruitment, participation, and retention. These models are particularly relevant in low-resource settings and regions with high HIV incidence.
Government Initiatives and Global Collaboration
Public-private partnerships and funding from organizations such as UNAIDS, the National Institutes of Health, the Gates Foundation, and the World Health Organization continue to accelerate HIV clinical research. Regulatory fast-track mechanisms are supporting the evaluation of promising therapies, while diversity initiatives are encouraging broader representation across ethnic, demographic, and geographic populations.
Market Segment and Regional Outlook
Phase outlook: The Phase I segment is projected to reach US$968.4 million by 2032, growing at a CAGR of 3.8%. The Phase II segment is forecast to expand at a CAGR of 6.1% over the analysis period. United States: The U.S. HIV clinical trials market was valued at US$412.3 million in 2025. China: China is forecast to grow at a CAGR of 8.1%, reaching US$439.2 million by 2032. Additional markets: The report evaluates growth patterns across Canada, Japan, Germany, the wider European market, Asia-Pacific, Latin America, the Middle East, and Africa.
Report Scope
The report analyzes the global HIV clinical trials market by value and provides forecasts from 2025 through 2032. Market segmentation includes:
Phase: Phase I, Phase II, Phase III, and Phase IV. Study design: Interventional, observational, and expanded-access studies. Sponsor: Pharmaceutical and biopharmaceutical companies, nonprofit organizations, and other sponsors. Geography: United States, Canada, Japan, China, Europe, Asia-Pacific, Latin America, the Middle East, and Africa, with analysis of selected countries and regional markets.
Strategic Value of the Report
Independent annual market analysis and forecasts presented in US$ million. Assessment of major growth drivers, restraints, emerging technologies, and commercial opportunities. Competitive intelligence covering leading companies and their presence across key geographic markets. Segment-level and regional insights designed to support investment, market-entry, partnership, and product-development decisions. Company profiles and one year of complimentary updates covering relevant market developments.
Companies Featured
Companies and organizations covered include AbbVie Inc.; AIDS Clinical Trials Group; AstraZeneca plc; Bristol-Myers Squibb Company; Charles River Laboratories International, Inc.; Gilead Sciences, Inc.; GlaxoSmithKline plc through ViiV Healthcare; HIV Vaccine Trials Network; ICON plc; IQVIA Holdings Inc.; Janssen Pharmaceutical Companies; Merck & Co., Inc.; Parexel International Corporation; Pfizer Inc.; PPD, Inc.; Roche Holding AG; Sanofi S.A.; SGS SA; Syneos Health; and WuXi AppTec.
Domain Expert Insights
The report tracks early market signals emerging from expert discussions, company activity, scientific conferences, keynotes, panel sessions, corporate disclosures, annual reports, institutional publications, and other validated intelligence sources. These perspectives provide additional context for assessing technological progress, competitive positioning, regional market structures, and strategic direction.
Competitive analysis extends beyond a single global market share estimate. Where analytically relevant, the report evaluates market share across major regions to reflect differences in local trial infrastructure, sponsor participation, regulatory conditions, research funding, and therapeutic pipelines. This approach connects emerging signals with the developments most likely to influence the future of the global HIV clinical trials market.
Key Attributes
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment